PubMed Health⌕ Search

Biomedical subjects

D Novick

Publications and source records attributed to D Novick.

78 records · Page 5Linked to original sources
PubMed1983

Affinity chromatography of human fibroblast interferon (IFN-beta 1) by monoclonal antibody columns.

Eight hybridomas secreting monoclonal antibodies specific to human fibroblast interferon (IFN-beta 1) were identified by a new screening procedure based on immune precipitation with a second antibody and recovery of interferon activity from the immune precipitate. Immunoadsorbents were prepared from these monoclonal antibodies and used for purification of IFN-beta 1. Electrophoretically pure IFN-beta 1, having a specific activity of 3 X 10(8) to 6 X 10(8) units/mg was obtained by a single passage of partially purified IFN-beta 1 on these immunoadsorbents.

Animals↗
PubMed1982

Monoclonal antibodies to human alpha-interferon and their use for affinity chromatography.

A new screening procedure has been developed and used for the identification of three hybridomas secreting monoclonal antibodies to human leukocyte interferon (IFN-alpha). The screening procedure is based on immune precipitation with a second antibody, acid dissociation of the precipitate, and bioassay of the recovered interferon. This procedure selects for monoclonal antibodies that are suitable for affinity chromatography, as demonstrated by construction of immunoadsorbents from these monoclonal antibodies and purification to homogeneity in IFN-alpha.

Animals↗
PubMed1980

Immune regulation of experimental myasthenia.

Experimental autoimmune myasthenia gravis (EAMG) is an appropriate model for studying the molecular origin, immunological mechanism and regulation of myasthenia gravis. Several approaches are being utilised for the regulation of the immune response to AChR and for immunosuppression of EAMG: Corticosteriods and azathioprine can suppress EAMG concomitantly with suppression of immune responses to AChR. High dose cyclophosphamide treatment in mice facilitates the onset of EAMG and results in a selective suppression of the humoral response to AChR whereas the cellular response is enhanced. Specific immunosuppression of EAMG is achieved by using a nonmyasthenic, denatured AChR preparation which cross reacts with the intact receptor. Various degradations and modifications of AChR are being performed in order to identify the smallest molecular entity responsible for the myasthenic activity of AChR. Studies on specific monoclonal antibodies, anti-idiotypes, and on the effect of measles virus on EAMG are being described and their possible significance in regulating myasthenia are being discussed.

Acetylcholine↗
PubMedDate not supplied

Progress in the psychotherapy of mood disorders: studies from the Western Psychiatric Institute and Clinic.

UNLABELLED: During the last three decades, we have witnessed dramatic improvements in both the psychosocial and pharmacological treatments of affective disorders. Administered in concert with the new medications advances in pharmacology have produced, disorder-specific psychosocial treatments have further improved the prognosis and course of bipolar and unipolar disorder. METHODS: We review our research on unipolar and bipolar disorder and their treatment, in particular interpersonal psychotherapy (IPT) and modifications thereof. RESULTS: We provide empirical evidence that IPT is an efficacious acute and maintenance treatment for affective disorders. Our cumulative research and clinical experience suggest that interpersonal relations and circadian and social rhythms influence affective illnesses and that psychotherapy may aid in normalizing problems in these areas for patients with affective illnesses. CONCLUSIONS: Despite the excitement generated by the recent progress in research on mental disorders and their treatment, we are yet to fulfill the promise that the explosion of knowledge about targeted pharmacotherapies or psychotherapies would seem to offer. To move our field forward, we must continue to apply scientific rigor and thought to understanding the suitability of current nomenclatures, the impact of comorbid psychiatric and medical illnesses and symptoms on the manifestation and treatment of affective disorders, and the practicality of widespread utilization of new treatments.

Aged↗
PubMedDate not supplied

[The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].

INTRODUCTION: To describe the baseline findings and study population of the Spanish sample of the Schizophrenia Outpatient Health Outcomes (SOHO) Study. METHOD: The SOHO study is an ongoing, large, prospective, long-term observational study of schizophrenia treatment in 10 European countries. The study population consists of outpatients who initiate therapy or change to a new antipsychotic. RESULTS: A total of 86 investigators enrolled 2,020 in Spain (10,972 patients in Europe). 64 % of patients were men and the mean age was 38.7 years. The Spanish SOHO study sample had considerable functional impairment at baseline. The main reason for change of therapy was lack effectiveness followed by intolerability. Patients included in the study and those receiving their first antipsychotic for schizophrenia are most likely to receive an atypical agent. CONCLUSION: The Spanish SOHO study population appears to represent the Spanish outpatients with schizophrenia in whom a treatment decision is required. Baseline findings reflect Spanish clinical practice with respect to patients treated with individual antipsychotics.

Adult↗